In October 2018, settlements in the AbbVie’s AndroGel lawsuits FINALLY appear ready to resolve. The drug company and plaintiffs’ lawyers are dotting the i’s and crossing the t’s on a settlement agreement that would resolve thousands of testosterone cases. (June 2019 Update: $775 million.)
Lawsuits had been filed claiming that the makers of Androgel, AbbVie, failed to warn thousands of men about the potential side-effects of the drug. These side-effects include heart attacks, blood clots, stroke, and even sudden death in extraordinary cases. As the litigation wheels start turning here, AbbVie is trying to gum them up with objections to slow down the process. You could say everything is going according to plan…
If you are reading this you probably already know this but let’s recap where were are. Currently, there are about 7,000 lawsuits against AbbVie percolating around the federal court system. The various suits allege that the makers of Androgel, AbbVie, neglected to warn thousands of men about the serious side effects of the “Low-T” treatment drug. This drug has certainly been a big hit, understandably so considering that it promises men physical enhancement to counteract the forces of aging. But thousands of lawsuits -allege that low-T drugs can lead to heart attack, stroke, pulmonary embolism, deep vein thrombosis, or other injuries, prompting men across the U.S. to sue AbbVie and the other manufacturers for not being adequately warned of the risks.
That really is what this is about. No one — at least not many people — are calling for a low-T recall. The risk might outweigh the benefit for some although probably not many of us. It is about giving patients and doctors a choice. Tell us what can happen and let us make the call. They are giving this warning now. They should have given it to us before. That is what these lawsuits are about.